Presenting seven abstracts demonstrating consistency of effect, long-term safety, and reduced progression of disease with givinostat Results also demonstrate delayed respiratory decline withgivinostat ITF Therapeutics LLC, the U.S. affiliate of Italfarmaco, today announced that seven abstracts have been accepted as poster presentations at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference to be held […]

(NASDAQ:KNSA), LONDON, Feb. 20, 2025 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 25, 2025 at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2024 financial results and recent portfolio execution. A live webcast will

(NASDAQ:VNOM), Travis D. Stice to transition from role as Chief Executive Officer Kaes Van't Hof, current President, will assume Chief Executive Officer role Austen Gilfillian, current Vice President, has been promoted to President Trevor Stoltz has been promoted to Vice President, Business Development John Phillips has been promoted to Vice President, Land MIDLAND, Texas, Feb.

(NASDAQ:FANG), Travis D. Stice to step down as Chief Executive Officer, effective as of the Company's 2025 Annual Meeting of Stockholders; will remain as Executive Chairman through the Company's 2026 Annual Meeting of Stockholders Kaes Van't Hof, current President, will assume Chief Executive Officer role and will join the Board of Directors effective as of

(NasdaqGM:TVTX), Company to submit sNDA around the end of 1Q 2025 seeking traditional approval of FILSPARI(R) (sparsentan) for FSGS Net product sales of FILSPARI totaled $50 million in 4Q 2024; $132 million for full year 2024 Net product sales totaled $74 million in 4Q 2024; $227 million for full year 2024 SAN DIEGO, Feb. 20,

(NASDAQ:ASUR), AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) — Asure Software, Inc. (“Asure” or the “Company”) (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management (HCM) software solutions, announced today that the Company will hold a conference call on Thursday, March 6, 2025 at 4:30 p.m. Eastern time to discuss its financial results for

(NasdaqGM:XENE), VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27,

(NASDAQ:WSC), PHOENIX, Feb. 20, 2025 (GLOBE NEWSWIRE) — WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced fourth quarter and full year 2024 results including key performance highlights and market updates. The Company also announced its outlook for full year 2025. Q4 20241,2 Generated revenue of

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your TELUS International (Cda) Inc. (NYSE:TIXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/telus-international-lawsuit-submission-form?prid=131034&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your BioAge Labs, Inc. (NASDAQ:BIOA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bioage-labs-inc-lawsuit-submission-form?prid=131033&wire=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or